Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension

Aletta E. Schutte 1,2,3*, Tazeen H. Jafar 4,5†, Neil R. Poulter 6†,*
Albertino Damasceno 7†, Nadia A. Khan 8,9†, Peter M. Nilsson 10†, Jafar Alsaid 11,12†, Dinesh Neupane 13†, Kazuomi Kario 14†, Hind Beheiry 15†,
Sofie Brouwers 16,17, Dylan Burger 18†, Fadi J. Charchar 19,20†,*
Myeong-Chan Cho 21, Tomasz J. Guzik 22†, Ghaizi F. Haji Al-Saedi 23, Muhammad Ishaq 24, Hiroshi Itoh 25†, Erika S.W. Jones 26†, Taskeen Khan 27, Yoshihiro Kokubo 28, Praew Kotruchinth 29, Elizabeth Muxfeldt 30†,
Augustine Odili 31, Mansi Patil 32, Udaya Ralapanawa 33, Cesar A. Romero 34†, Markus P. Schlaich 35,36,37†, Abdulla Shehab 38, Ching Siew Mooi 39,†
U. Muscha Steckelings 40, George Stergiou 41†, Rhian M. Touyz 42, Thomas Unger 43, Richard D. Wainford 44, Ji-Guang Wang 45, Bryan Williams 46, Brandi M Wynne 47, and Maciej Tomaszewski 48,49,50†

1School of Population Health, University of New South Wales, Kensington Campus, High Street, Sydney 2052 NSW, Australia; 2The George Institute for Global Health, King Street, Newtown, Sydney NSW 2052, Australia; 3Hypertension in Africa Research Team, SAMRC Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom 2520, South Africa; 4SAMRC Development Pathways for Health Research Unit, School of Clinical Medicine, University of the Witwatersrand, 1 Jan Smuts Ave, Braamfontein, Johannesburg, 2000, South Africa; 5Program in Health Services and Systems Research, Duke-NUS Medical School, Department of Renal Medicine, 8 College Rd., Singapore 169857, Singapore; 6Duke Global Health Institute, Duke University, 310 Trent Dr, Durham, NC 27710, USA; 7Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Australia; 8Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia; 9Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; 10Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; 11International University of Africa, Khartoum, Sudan; 12Department of Cardiology, Cardiovascular Center Aalst, OLV Clinic Aalst, Aalst, Belgium; 13Department of Experimental Pharmacology, Faculty of Pharmacy and Medicine, Vrije Universiteit Brussel, Brussels, Belgium; 14Kidney Research Centre, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; 15Health Innovation and Transformation Research, Federation University, Ballarat, Victoria, Australia; 16Department of Physiology and Anatomy, University of Melbourne, Melbourne, Victoria, Australia; 17Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea; 18Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; 19Baghdad College of Medicine, Baghdad, Iraq; 20Pakistan Hypertension League, Karachi, Pakistan; 21Division of Endocrinology, Metabolism and Nephrology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8585, Japan; 22Division of Nephrology and Hypertension, Groote Schuur Hospital and Kidney Research Hypertension Unit, University of Cape Town, Cape Town, South Africa; 23Department of Public Health Medicine, University of Pretoria, Pretoria, South Africa; 24Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan; 25Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 26University Hospital Clementino Fraga Filho, Hypertension Program, Universidade Federal do Rio de Janeiro, Brazil; 27Circulatory Health Research Laboratory, College of Health Sciences, University of Abuja, Abuja, Nigeria; 28Department of Nutrition and Dietetics, Asha Kiran IHC Hospital, Chinchwad, India; 29Faculty of Medicine, University of Peradeniya, Kandy, Central Province, Sri Lanka; 30Renal Division, Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA; 31Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Australia; 32Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia; 33Department of Nephrology, Royal Perth Hospital, Perth, Western Australia, Perth, Western Australia, Australia; 34College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates; 35Department of Family Medicine, Faculty of Medicine and Health Sciences, University Putra Malaysia, Malaysia; 36Department of Cardiovascular & Renal Research Institute, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; 37Hypertension Centre STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece; 38Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada; 39Carim - Cardiovascular Research Institute, Maastricht University, Maastricht, The Netherlands; 40Department of Pharmacology & Experimental Therapeutics and the Whither, Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA; 41Division of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 42Institute of Cardiovascular Science, University College London (UCL), National Institute for Health Research (NIHR), UCL Hospitals Biomedical Research Centre, London, UK; 43Department of Internal Medicine, Division of Nephropathy & Hypertension, University of Utah, Salt Lake City, UT, USA; 44Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, UK; 45Manchester Heart Centre, Manchester University NHS Foundation Trust, Manchester, UK; 46Academic Medical Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.

Received 6 March 2022; revised 13 May 2022; accepted 31 May 2022

* Corresponding author. Tel: +61 450 315 918, E-mail: a.schutte@unsw.edu.au (A.E.S.); Tel: +44 161 275 0232, E-mail:maciej.tomaszewski@manchester.ac.uk (M.T.)
† These authors contributed equally to the study.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Raised blood pressure (BP) is the leading cause of preventable death in the world. Yet, its global prevalence is increasing, and it remains poorly detected, treated, and controlled in both high- and low-resource settings. From the perspective of members of the International Society of Hypertension based in all regions, we reflect on the past, present, and future of hypertension care, highlighting key challenges and opportunities, which are often region-specific. We report that most countries failed to show sufficient improvements in BP control rates over the past three decades, with greater improvements mainly seen in some high-income countries, also reflected in substantial reductions in the burden of cardiovascular disease and deaths. Globally, there are significant inequities and disparities based on resources, sociodemographic environment, and race with subsequent disproportionate hypertension-related outcomes. Additional unique challenges in specific regions include conflict, wars, migration, unemployment, rapid urbanization, extremely limited funding, pollution, COVID-19-related restrictions and inequalities, obesity, and excessive salt and alcohol intake. Immediate action is needed to address suboptimal hypertension care and related disparities on a global scale. We propose a Global Hypertension Care Taskforce including multiple stakeholders and societies to identify and implement actions in reducing inequities, addressing social, commercial, and environmental determinants, and strengthening health systems implement a well-designed customized quality-of-care improvement framework.

Keywords

Epidemiology • Hypertension • Global • International • Cardiovascular disease • Regions • Inequity • Prevention • Awareness • Treatment • Control

A video prepared by authors can also be viewed here: Supplementary material

1. Introduction

Raised blood pressure (BP) is the leading attributable risk factor for death globally, accounting for 10.8 million deaths in 2019. During the past four decades, the number of people with hypertension has increased by 90%, mainly in low- and middle-income countries (LMICs). The main drivers for this rise are population growth, ageing, unhealthy environments, and behaviours (sedentary lifestyles, poor diets, obesity, alcohol abuse), and differences in access to quality care. Consequently, there are considerable disparities in age-standardized BP levels, BP control, and related cardiovascular disease (CVD) burden globally, among and within countries.

In most high-income countries (HICs), the observed age-standardized BP levels have declined, and hypertension awareness and treatment have improved with control rates at ~50% (Figure 1). However, the highest BP levels have shifted from HIC to LMICs. BP levels rose in South and East Asia, and sub-Saharan Africa (SSA) with poor rates of awareness, treatment, and control (<10%), Moreover, populations in Central and Eastern Europe, the Middle East, and North Africa continue to have the highest BP levels and suboptimal BP control (~30%) (Figure 1).

Consequently, trends of hypertension-related CVD deaths declined more in HIC compared with LMICs, while the years lived with related disability increased in all countries, albeit more in LMICs (Figure 2). In addition, significant race-based disparities exist in BP control even within HICs, with certain subgroups more likely to be under-treated with worse BP control, and disproportionately affected by related cardiovascular complications.

The NCD Risk Factor Collaboration and Global Burden of Disease Collaboration have been pivotal in providing global statistics to demonstrate the alarming situation that we now face—an asymptomatic but sometimes asymptomatic but leading risk factor for death, amidst many other (urgent) global challenges such as COVID-19 and climate change. Major steps have already been taken to improve hypertension care globally, recognizing that drastic actions are urgently needed to turn the dial. These include the World Health Organisation (WHO)’s development of the HEARTS technical package to provide a strategic approach to improve cardiovascular health. Modules include Healthy lifestyle counselling, Evidence-based treatment protocols, Access to essential medicines and technology, Risk-based CVD management, Team-based care, Systems for monitoring, and an implementation guide. Their efforts have been supported by Resolve to Save Lives—a global public health organization that identified the urgency to prevent millions of deaths in LMICs from CVDs through speed, simplicity, and scale. The Lancet Commission on Hypertension urged for a life-course strategy by creating healthy environments, highlighted improving awareness, and actions on many elements of the WHO HEARTS package, such as workforce expansion, plus measurement and medication access (overcoming treatment inertia and improving non-adherence to medication). Despite numerous ‘calls to action’, limited improvement has been seen. But there are some success stories where clear improvements are evident. One example is the adoption of the HEARTS package in the Americas led by the Pan American Health Organisation. In <1 year, the proportion of those treated and who were controlled increased from 59 to 69% in Cuba.

The purpose of this paper is not to reiterate all well-known barriers, but to provide region-specific evidence and often unique perspectives from the ground level. In recognition of contributions by members of the International Society of Hypertension (ISH) to hypertension research over the last few decades, Cardiovascular Research has extended an invitation to the President of the Society to contribute a state-of-the-art review article summarizing the past, present, and future in hypertension around the globe. A call for an expression of interest has been sent to the ISH Council, Committees and Regional Advisory Groups. Expressions were reviewed considering expertise, global representation, career stage, and gender balance. Contributors were divided into eight working groups aligned with the key tasks and ISH global structure of Regional Advisory Groups, each led by an experienced ISH investigator. Further to internal review,
Figure 1 Change in absolute blood pressure control rates from 1990 to 2019 by country and sex (adapted with permission from the NCD Risk Factor Collaboration database\textsuperscript{4,5}). Red dots (control rates 1990), black dots (control rates 2019).
the ISH College of Experts selected external reviewers (including WHO, the European Society of Hypertension, and World Hypertension League). Their comments were addressed before submission to the journal. From the perspective of the ISH, this paper will thus outline:

1. Lessons learnt over the past 50 years. Key steps taken over the past decades in the management of hypertension including BP-lowering agents, the non-pharmacological management of hypertension, landmark trials, guidelines, treatment, and control.
2. The impact of raised BP worldwide. This section highlights unique region-specific challenges and opportunities based on evidence and experiences of ISH members. Regions include SSA, the Americas, Europe, the Middle East and North Africa, South and Central Asia, and the Asia Pacific;
3. Actions to ensure evidence-based hypertension care for cardiovascular risk reduction. This section provides strategies to improve hypertension care and to eliminate related disparities among and within countries.

2. Lessons learnt over the past 50 years

The history of BP measurement began almost three centuries ago (Table 1) whilst the main drug classes which dominate current clinical practice were developed between 30 and 60 years ago (Table 2). After their development, the newly developed agents were included in multiple clinical trials (Table 3), the results of which led to the development of national and international guidelines on hypertension management (Table 4). The initial section of this review attempts to record how the inter-relationships amongst these drug classes, trials, and guidelines relate to the evolution of clinical management of hypertension in the last five to six decades.

2.1 Blood pressure-lowering agents

The era of antihypertensive drug development started in 1930 (Table 2), albeit with drugs that had unpredictable efficacy and frequent adverse effects. In the 1940s and 1950s, ganglion-blocking agents, hydralazine,
and chlorothiazide were increasingly used and showed some evidence of the benefits of reducing BP. Only thiazide diuretics among these early antihypertensive drugs have survived as first-line agents until today. In the 1960s, central blockers of the sympathetic nervous system were developed, followed by β-blockers and later in the 1980s, calcium channel blockers (CCBs), the latter being one of the mainstays of current management. In 1977, angiotensin-converting enzyme inhibitors (ACEi) were synthesized and since then this drug class has played a major and increasing role in hypertension management and cardiovascular medicine. These drugs, together with the angiotensin receptor blockers (ARBs) which followed, remain the cornerstone of antihypertensive therapy for many patients. In the last 20 years, several new antihypertensive agents have been investigated for primary hypertension, including endothelin inhibitors, central renin–angiotensin system blockers, endothelial dysfunction modulators, and new aldosterone antagonists, and while none of them are recommended as first-line agents, spironolactone has been established as fourth-line therapy, optimal therapy for patients with resistant hypertension, and first-line therapy for primary aldosteronism.25

2.2 Non-pharmacological management of hypertension

Lifestyle improvement is a cornerstone of hypertension prevention, control and reducing the risk of CVD, and is recommended in all major guidelines.25–27 Dietary and lifestyle changes such as weight control, alcohol consumption reduction, smoking cessation, reduced dietary salt intake, and increased regular exercise not only improve cardiovascular health but reduce BP and improve hypertension control.30–36 Of non-pharmacological interventions, one of the most efficacious in lowering BP is the Dietary Approach to Stop Hypertension (DASH)37–39 underscoring the importance of a diet rich in fruits, vegetables, and low-fat dairy foods with reduced saturated and total fat, and reduced salt.40 Comprehensive lifestyle modification, when used as a combined intervention, provides added benefit.40

2.3 Landmark trials41–45

The results of early clinical trials in hypertension provided insights into both our understanding of the complications of high BP and optimal treatment. Hypertension pharmacotherapy is arguably the most studied evidence-base of any clinical intervention. Multiple seminal trials have shown that BP reduction is effective at reducing cardiovascular morbidity and mortality. Initially, diastolic BP was considered to be the primary target, as reflected by trial inclusion criteria, but soon, trials such as SHEP and SYST-EUR (Table 3) showed that treating isolated systolic hypertension is beneficial and in general, thereafter, more emphasis has been placed on systolic pressure as inclusion criteria for trials. As trial inclusion criteria changed, the definition of hypertension followed the evidence from being initially based only on diastolic BP to include systolic criteria and also changed from ≥160/90 to 140/90 mmHg.46 Other key questions followed regarding optimal treatment targets. This was addressed by a series of trials most recently the SPRINT trial (Table 3), which have informed gradually lower targets. A further pivotal question was—what is the best way of achieving these targets? The stepwise incremental therapy approach (‘Stepped care’) was introduced in the Hypertension Detection and Follow-Up (HDFP) trial in 1979 (Table 3) and was tested leading to huge improvements in clinical outcomes and survival. Finally, the question as to which drugs were the most effective in terms of preventing CV outcomes was assessed in a series of trials comparing older and newer medications and their combinations (e.g. ALLHAT, ASCOT-BPLA, LIFE, ANBP2, ACCOMPLISH, VALUE, etc.) (Table 3). Recently, the situation has changed, with all major hypertension guidelines now recommending single-pill combination (SPC) therapy as first-line treatment—a major update in the therapeutic approach to hypertension.

### Table 1 Major steps in the evolution of BP measurement19–21

| Year | Event                                                                 |
|------|-----------------------------------------------------------------------|
| 1733 | First intra-arterial BP measurement (Stephen Hales)                   |
| 1833 | First device with mercury bulb and glass column (Jules Herisson)      |
| 1854 | First non-invasive mechanical sphygmograph (Karl Vierordt)            |
| 1880 | Invention of sphygmomanometer (Siegfried Ritter von Basch)           |
| 1896 | Invention of cuff (Scipione Riva-Rocci)                              |
| 1905 | Identification of Korotkoff sounds (Nicolai Sergeivich Korotkoff)     |
| 1926 | Establishment of classic mercury sphygmomanometer                     |
| 1930 | Establishment of classic aneroid devices                              |
| 1961 | First ambulatory BP monitor (AT Himman)                               |
| 1976 | First automated oscillometric BP device patent                        |
| 1986 | First guidelines for office BP measurement (British Hypertension Society) |
| 1987 | Establishment of validation standards for BP monitors (US Association for the Advancement of Medical Instrumentation; British Hypertension Society) |
| 1995 | First guidelines for ambulatory and home BP monitoring (American Society of Hypertension) |
| 2005 | Ambulatory and home BP monitoring included in algorithm for diagnosing hypertension (Canadian Hypertension Education Program) |
| 2011 | Ambulatory BP monitoring recommended for diagnosing hypertension (UK National Institute of Health Excellence) |

### Table 2 Chronological steps in the development of major antihypertensive drugs

| Year | Drugs                                                                 |
|------|-----------------------------------------------------------------------|
| 1930s | Veratrum alkaloids (from the Lily plant family)                       |
| 1940s | Thiocyanates                                                         |
| 1950s | Ganglion blockers (Tetroethylammonium)                                |
| 1960s | Catecholamine depletors (Reserpine—Rauwolfia)                        |
| 1970s | Vasodilators (Hydralazine)                                           |
| 1980s | Peripheral sympathetic inhibitors (Guanethidine)                     |
| 1990s | Spironolactone                                                       |
| 2000s | Thiazide diuretics (Chlorothiazide)                                   |
| 1960s | Central adrenergic-2 agonists (Methyldopa, Clonidine)                |
| 1970s | β-Blockers (Propranolol)                                             |
| 1980s | Non-dihydropyridine calcium channel blockers (Verapamil)             |
| 1990s | Thiazide-like diuretics (Indapamide)                                  |
| 1970s | Alpha1-adrenergic-blockers (Prazosin)                                 |
| 1980s | Angiotensin-converting enzyme inhibitors (Captopril)                 |
| 1990s | Dihydropyridine calcium channel blockers (Nifedipine)                |
| 2000s | Angiotensin II type 1 receptor blockers (Losartan)                    |
| 2011  | Direct renin inhibitors (Aliskiren)                                   |
Table 3 Summary of landmark clinical trials that impacted hypertension treatment

| Study          | Design (medications)                                                                 | Main conclusion                                                                 | PMID    |
|----------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------|
| Hamilton et al. (1964) | Antihypertensive treatment in prevention of strokes and vascular complications | First controlled trial of antihypertensive therapies showing a significant reduction in strokes and other complications | 14090850 |
| VA-1st (1967)   | Hydrochlorothiazide, reserpine, and hydralazine vs. placebo                           | Mortality and morbidity benefit, reduced progression to malignant HTN in patients with severe diastolic HTN (115–129 mmHg) | 4862069 |
| VA-2nd (1970)   | Hydrochlorothiazide, reserpine, and hydralazine vs. placebo                           | Mortality and morbidity benefit, in moderately severe HTN (diastolic 90–115 mmHg) | 4914579 |
| HDFP (1979)     | Stepped care vs. usual care; drugs: chlorthalidone, diuretics, reserpine, methyldopa, hydralazine, guanethidine | First study showing mortality and morbidity by aggressive, goal-directed BP management using incremental therapy in contrast to therapy with no target BP. This study set the ground rules for future management of HTN using incremental therapy—a new concept in managing chronic diseases | 490882 |
| MRC (1985)      | Bendroflumethiazide or propranolol vs. placebo in mild diastolic HTN                  | Reduction in strokes and all CV events but not total mortality                  | 2861880 |
| EWHPE (1986)    | Hydrochlorothiazide/triamterene vs. placebo                                          | First major RCT in elderly population showing decrease in MI/cardiac deaths      | 3475430 |
| SHEP (1991)     | Chlorthalidone with a step-up to atenolol or reserpine                               | First RCT in isolated systolic HTN, which had been considered benign before      | 2046107 |
| MRC (1992)      | Elderly patients (65–74 years old) randomized to diuretic, β-blocker, or placebo      | Hydrochlorothiazide and amiloride reduce the risk of stroke, coronary events, and all cardiovascular events in older hypertensive adults | 1445513 |
| TOMHS (1993)    | Chlorthalidone vs. acetubolol vs. doxazosin vs. amlodipine vs. enalapril (all combined with nutritional/hygienic advice) vs. placebo/nutritional advice alone | Comparison of 5 classes and antihypertensive medications in addition to nutritional/hygienic advice | 8336373 |
| SYST-EUR (1997) | Nitrendipine with the possible addition of enalapril and hydrochlorothiazide or matching placebo in patients (>60 years old) with SBP 160–219 mmHg | First CCB RCT—in elderly with isolated systolic HTN, nitrendipine reduces the rate of cardiovascular complications | 9297994 |
| DASH (1997)     | Three diet regimens including combination DASH diet                                   | DASH diet reduced BP in both hypertensive and normotensive groups                | 9099655 |
| HOT (1998)      | Three DBP targets: ≤90; ≤85, or ≤80 mmHg; achieved by stepwise therapy with felodipine 5–10 mg/day; add ACE inhibitor or β-blocker then add thiazide diuretic | Large RCT; no significant difference in outcome between all three groups although all achieved DBP < 85 mmHg | 9635947 |
| UKPDS (1998)    | BP control comparison with tight control (BP target < 150/85 mmHg), vs. less tight (< 180/105 mmHg) using captopril and atenolol | In T2D tight BP control achieved more macro- and micro-vascular morbidity and mortality benefits than tight blood glucose control | 9732337 |
| Syst-China (2000) | Nitrendipine with the possible addition of captopril and/or hydrochlorothiazide in patients (>60 years old) with SBP 160–219 mmHg | Stepwise antihypertensive drug treatment improved prognosis, with particular benefit in patients with T2D | 10647760 |
| DASH (2001)     | Low sodium DASH diet                                                                 | Established sodium dietary levels in BP control                                 | 11136953|
| LIFE (2002)     | Losartan vs. atenolol                                                                | Losartan confers benefits beyond reduction in BP and is better tolerated than atenolol | 11937178|
| AASK (2002)     | Compared different BP goals. Mean BP ≤92 mmHg vs. BP ≤102–107 mmHg in African Americans using metoprolol/ramipril/amlodipine to slow down renal failure | Tighter BP control failed to reduce GFR decline although hypertensive nephrosclerosis was non-significantly slowed down | 12435255|
| ALLHAT (2002)   | Angiotsin-converting enzyme inhibitor (ACE-I; lisinopril), calcium channel blocker (amlodipine), and alpha-blocker (doxazosin) vs. thiazide-like diuretic (chlorthalidone) | Largest antihypertensive trial. Use of thiazide-like diuretics should be preferred at the start of therapy unless contraindicated | 12479763|
| ANBP2 (2003)    | Thiazide vs. ACE-I                                                                   | Non-significantly different outcomes; Australia                                 | 12584366|
| VALUE (2004)    | Valsartan vs. amlodipine in cardiac morbidity and mortality reduction in hypertensive patients at high cardiovascular risk | No difference in cardiac outcomes between treatments. Importance of prompt BP control in hypertensive patients at high cardiovascular risk | 15207952|
| ASCOT (2005)    | Atenolol/thiazide vs. amlodipine/perindopril                                        | CCB/ACE-I combination gives much better outcomes than older regimen of β-blocker and hydrochlorothiazide | 16154016|

Continued
The de
2.4 Guidelines
The definition or diagnostic threshold of hypertension changed from an
2.5 Treatment and control
Reports of BP surveys in the US spawned the term ‘rule of halves’ in a
Continued

| Study (year) | Design (medications) | Main conclusion | PMID |
|-------------|----------------------|----------------|------|
| HYVET (2008) | (Indapamide±perindopril) vs. placebo in very elderly (≥80 years) | Mortality, CV events (including stroke) reductions; heart failure reduced by 64% | 18378519 |
| ACCOMPLISH (2008) | Comparison of ACE-I/CCB vs. ACE-I/diuretic | Benazepril ± Amlodipine—19.6% relative risk reduction of composite CV death/CV events (including strokes) | 19052124 |
| ACCORD (2010) | Compare intensive BP lowering <120 mmHg to conventional BP <140 mmHg in T2D | No significant benefit for intensive BP lowering in diabetics | 20228401 |
| SPRINT (2015) | Compare intensive BP lowering <120 mmHg to conventional BP <140 mmHg in non-diabetics without prior strokes | Intensive lowering of systolic BP goal <120 mmHg in non-diabetic population report substantial reduction in major cardiovascular events with intensive BP lowering in older patients, intensive lowering of systolic BP to 110–130 mmHg showed a lower incidence of cardiovascular events than standard the target traditional | 26551272 |
| STEP (2021) | Compare intensive BP lowering to 110–130 mmHg to a target of 130–150 mmHg in patients aged 60–80 years | | 34491661 |

PMID, Pubmed ID; HTN, hypertension; BP, blood pressure; CV, cardiovascular; RCT, randomized clinical trial; CCB, calcium channel blocking agent; DASH, dietary approaches to stop hypertension; DBP, diastolic blood pressure; T2D, type 2 diabetes mellitus; GFR, glomerular filtration rate; ACE-I, angiotensin-converting enzyme inhibitors. Trial full names listed in Pubmed papers.
Table 4  Summary of the development of hypertension guidelines

| WHO/ISH | BHS/NICE | ESH | ACC/AHA | Canada | JSH |
|---------|----------|-----|---------|--------|-----|
| WHO/ISH 1999 | | | | | |
| Definition of hypertension: | | | | | |
| BP ≥140/90 | | | | | |
| BP goal: 130/85 | | | | | |
| 1st line medication: ARB, ACE-i, CCB, diuretics, α-blocker, β-blocker | | | | | |
| WHO/ISH 2003 | | | | | |
| BP target | | | | | |
| Low, intermediate risk: | | | | | |
| SBP < 140 | | | | | |
| High risk: <130/80 | | | | | |
| Low-dose diuretics is recommended | | | | | |
| Cost-effectiveness | | | | | |
| 2013 ISH/ASH | | | | | |
| BP target | | | | | |
| General: <140/90 | | | | | |
| Age > 80 years: <150/90 | | | | | |
| 2011 BHS/NICE | | | | | |
| Focusing on ABPM and HBPM | | | | | |
| BP target | | | | | |
| <80 years: <140/90 | | | | | |
| ≥80 years: <150/90 | | | | | |
| First-line medication: ACE-I | | | | | |
| >55 years: CCB | | | | | |
| β-blocker is not recommended | | | | | |
| 2014 JNC-8 | | | | | |
| BP target, General: | | | | | |
| <140/90 | | | | | |
| Age ≥60 years: <150/90 | | | | | |
| 2015 AHA/ACC/ASH | | | | | |
| BP target, General: | | | | | |
| <130/80 | | | | | |
| Age ≥65 years: <150/90 | | | | | |
| 2015 CHEP recommendation | | | | | |
| Preferential use of electronic upper arm device | | | | | |
| Diagnosis of hypertension based on out-of-office BP 2016 | | | | | |
| 2016 JSH2016 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2017 ACC/AHA | | | | | |
| Change in the definition of hypertension | | | | | |
| ≥130/80 | | | | | |
| BP target, General: | | | | | |
| <130/80 | | | | | |
| >65 years: <SBP 130 | | | | | |
| 2018 NICE guideline | | | | | |
| | | | | | |
| Hypertension in adults: diagnosis and management | | | | | |
| ESC/ESH2018 | | | | | |
| BP target | | | | | |
| General: <140/90 | | | | | |
| Age ≥60 years: <150/90 | | | | | |
| Lower limit: DBP 170 | | | | | |
| First-line medication: | | | | | |
| RAS inhibitor (ARB or ACE-I) + CCB or diuretics | | | | | |
| 2019 NICE guideline | | | | | |
| | | | | | |
| ISH 2020 global hypertension practice guidelines | | | | | |
| For application in both low- and high-resource settings | | | | | |
| ESH/ESC2013 | | | | | |
| BP target, General: | | | | | |
| <140/90 | | | | | |
| Age ≥60 years: <150/90 | | | | | |
| Diabetes: <140/85 | | | | | |
| First-line medication: | | | | | |
| ARB, ACE-I, CCB, diuretics, β-blocker | | | | | |
| 2020 JSH2020 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2021 JSH2021 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2022 JSH2022 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2023 JSH2023 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2024 JSH2024 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2025 JSH2025 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2026 JSH2026 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2027 JSH2027 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2028 JSH2028 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2029 JSH2029 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2030 JSH2030 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2031 JSH2031 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2032 JSH2032 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2033 JSH2033 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2034 JSH2034 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
| 2035 JSH2035 | | | | | |
| BP target of the old: | | | | | |
| <140–160/90 | | | | | |
were controlled. Only 13% of those aware were classified as controlled.72

...show awareness rates of ∼37% of all hypertensives.73, and control from 16 to 55%.

The improvements in awareness, treatment, and control rates in several LMICs have reportedly plateaued in recent years. In LMICs, contemporary (2005–16) levels of awareness are worse than in HICs at 39%, of whom 76% were treated, and overall, only ∼37% of all hypertensives.74

The May Measurement Month (MMM) global BP awareness campaign reports the most contemporary data (2017 on over 2.7 million people screened in 2018 and 2019, it is clear that the vast majority of people with raised BP are unaware (Figure 3), with evident inequities apparent between many HIC and LMICs—albeit based on opportunistic screening (Methods in Supplementary material online).

In the subsequent section, brief summaries are given for each global region, with insights on the epidemiology, unique challenges, and opportunities to improve BP control.

3.1 Sub-Saharan Africa
Countries: Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Democratic Republic of Congo, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Togo, Uganda, United Republic of Tanzania, Zambia, Zimbabwe.

3.1.1 Epidemiology
During the last few decades, SSA has shown a constant increase in the prevalence of hypertension, without any significant improvement in the levels of awareness, treatment, and control. The MMM campaigns of 2018 and 2019 demonstrated that, when compared with other regions in the world, SSA had lower levels of awareness, treatment, and control of hypertension: 40.5%, 32.1%, and 15.4% respectively (Figure 4). Unfortunately, MMM may not represent the underlying population because sampling was by convenience. However, in a recently published analysis of more than 104 million participants from population-representative studies, SSA shared with Oceania and South Asia the lowest levels of awareness, treatment, and control of hypertension in the world, much lower than the ones described in the MMM analyses.75
3.1.2 Challenges

- A major challenge in SSA is that, as one of the most under-developed regions in the world, it faces considerable poverty. Geographical distances and political instability can significantly limit access to healthcare and emergency medical services. This is coupled with inadequate healthcare systems with limited guidelines.

- Due to poverty but also due to cultural beliefs, many patients first see a traditional healer, which is much more accessible than a medical doctor. It has also been well described that traditional herbal medicines without any evidence for effectiveness are used either alone or together with allopathic medicines to treat hypertension.

- Unfortunately, there is a dearth of information available for the region due to administrative restrictions and limitations to research. The lack of political will to provide access to healthcare, corruption, and limited healthcare system transparency restricts the ability to manage non-communicable diseases (NCDs). Furthermore, political leaders often deny NCD-associated health problems.

- Lack of funding means that healthcare professionals may lack the skills, training, and resources to manage hypertension. Limited healthcare system funding also means that BP-lowering medications (when available) are often self-funded but extreme poverty makes hypertension control unreachable for the majority.

- Education and literacy levels are low throughout SSA, raising concerns about population awareness of NCDs; a high degree of poor adherence to medication and suspicion towards Westernized healthcare compound these problems.

- Another challenge on the continent is hypertension-related health disparities. Reasons for health disparity in Africa include socioeconomic status (SES) and educational background, location, religion, and colonial relationships. Depending on the dimensions under consideration, the disparities cut across countries, different regions of the continent, or even within countries. The situation within the continent is heterogeneous, with more developed countries like Mauritius, Seychelles, South Africa, and Namibia showing a level of BP control that is sometimes more than double that of poorer countries. Race and ethnicity are considered major contributors to health disparities, particularly in higher-income countries. In small populations, such as rural Pygmies that continue to follow hunter-gatherer lifestyles very low levels of urinary sodium excretion and very low BP levels are still reported.

- Cardiovascular risk in Africa appears to be greater due to a loss of these traditional lifestyles with a rapid transition towards western lifestyles, and a combination with genetic risk, leading to early hypertension-mediated organ damage seen during urbanization.

- In HIC, higher SES is associated with a lower prevalence of hypertension. In SSA, the association between hypertension and SES is less clearly defined with differences noted based on sex, including a lower prevalence in women who are consistently better treated and controlled than men. There are disparities in risk factors associated with hypertension, such as salt consumption, obesity, alcohol intake, and cigarette smoking. A wide range in alcohol consumption exists across different countries in Africa. Within these countries, cultural and religious beliefs also affect reported alcohol consumption, including systematic under-reporting of and in enacting the legislature against alcohol.

- The prevalence of obesity has been on the increase in the entire sub-region. However, the rate of increase varies widely across different...
regions. Between 1990 and 2015, the prevalence of those overweight tripled from 6.4 to 21% in the Southern African region, while in Eastern Africa, the prevalence increased marginally from 4.5 to 5%. In-country prevalence of obesity varies according to a person’s SES with those in higher-income classes more likely to be obese.84–87

- Access to antihypertensive medication and hypertension-related health care services vary widely within and across countries.88 The national essential medicine list in various countries is not regularly updated in line with WHO Essential Medicines List (EML) and as such guideline-recommended therapies may not be adhered to, a practice necessary to ensure BP control. Generally, Africa has low availability of hypertension services, but this is particularly evident in rural areas.

- Due to the well-documented shortage of physicians in SSA, the task-sharing strategies, whereby non-physician health workers adopt roles that include the diagnosis and prescription of antihypertensive medications, have been found to be effective in controlling hypertension. These policies are yet to be adopted throughout SSA.

- Disparities in antenatal care may widen the gap in the burden of hypertension between the poor and the rich in later life. Huge differences exist in the burden of pre-eclampsia, malaria in pregnancy, and low birth weight across different regions of Africa. Earlier reports have

---

**Figure 4** Awareness, treatment, and control rates of MMM screenees defined as hypertensive (2018 and 2019). Percentage of screenees who were hypertensive: Sub-Saharan Africa: 26.6% of total (N = 370,395) screened. Americas: 40.8% of total (N = 449,117) screened *excluding the USA and Canada. Europe: 43.1% of total (N = 186,159) screened. Middle-East and North Africa: 28.3% of total (N = 139,908) screened. South and Central Asia: 31.3% of total (N = 864,394) screened. Asia Pacific: 34.1% of total (N = 1,001,001) screened.
indicated that individuals who developed in an unfavourable intrauterine milieu have a greater predisposition to early-onset hypertension.13

### 3.1.3 Opportunities to improve BP control
African populations are particularly sensitive to salt intake.89 Although several global reports have noticed that salt consumption in Africa is low, the data are overall weak and there is a need to strengthen data on salt intake. More recent data show that in some cases, the consumption of salt is double the level recommended by the WHO with a large amount of discretionary added salt.90 With the recent evidence of the beneficial effects of salt substitutes,91 this could be a cost-effective way for primary prevention of hypertension.

In terms of primary prevention, infant and maternal health programs have strong external support. The correct diagnosis of hypertension during pregnancy and the prevention of pre-eclampsia, which are extremely common in SSA, could also reduce the long-term consequences of chronic hypertension, stroke, heart failure, acute myocardial infarction, and chronic kidney disease (CKD).92 Hypertension may be defined as a health priority, but, in practice, the limited national funding is preferentially allocated to infectious disease and maternal/child health programs. The result is that NCD care is dependent on donations and competes for funding with infectious disease and HIV programs. The integration of NCD clinics with HIV care has already proven to be effective. This partnership, if well used, would increase the levels of awareness, treatment, and control, mostly in the eastern and southern region of Africa where HIV is still extremely prevalent.

The first step in addressing the challenges associated with the limited hypertension healthcare in Africa is an acknowledgement by funders that healthcare is a basic right and action plans need to be put in place to provide access to healthcare. This includes a strong emphasis on strengthening primary healthcare (as a global WHO priority), including staffing, training, availability, and affordability of good quality generic medications, mobile clinical services, nurse-led services, and engaging with traditional healthcare providers. Specific opportunities include:

- Decrease salt consumption with national policies to decrease the amount of sodium in food and promote the use of potassium salt substitutes.
- Integrate hypertension control into well-established HIV or maternal and child health programs that are financed and functioning well.
- Team-based care, not only with nurses but by using innovative approaches involving community health workers, lay people, and even traditional healers.
- Roll-out and scale-up of the WHO HEARTs package as a model to strengthen primary care using a public health approach.

### 3.2 The Americas
Countries: Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, USA, Uruguay, Venezuela

#### 3.2.1 Epidemiology
The Americas population comprises over 1 billion persons among 36 diverse countries over a land area of 42 million km². Hypertension surveillance surveys use varying measurement techniques, differing cut-point definitions of hypertension and bear varying degrees of completeness across countries.4,93–97 Using a similar ≥140/90 mmHg cut-point for hypertension, prevalence ranges from a high of 43% in Latin America93 to 29% in the USA,83 and 23% in Canada,95 with men generally having a higher prevalence than women.93,94 Special mention should be made of the Caribbean countries where hypertension prevalence has continued to increase, with figures exceeding 45% in some countries.4,18 Awareness of hypertension is generally high throughout the Americas (83% USA, 77% Canada, and 63% in Latin America) (Figures 3 and 4).93–97 Among those aware of their diagnosis, 93% in Canada, 73% in the USA, and 49% in Latin America were treated. Overall, among those with hypertension, control is suboptimal (58% in Canada, 51% in the USA, and 21% in Latin America) and with the pandemic, control may have fallen further.98

#### 3.2.2 Challenges
The main challenges to achieving hypertension control include a poor diet, increased sedentariness, rising obesity, and limited access to health services and low-cost medications.

- Approximately 10% of the US population is without affordable health-care insurance,99 and the uninsured/underinsured are more likely to have poor BP control.100
- Another principal cause for suboptimal hypertension control is medication non-adherence and therapeutic inertia. In Canada, despite a universal healthcare system and access to low-cost medications, almost 50% of patients with hypertension are non-adherent to medications.101 In Latin America, treatment inertia remains a problem, where there is suboptimal intensification of therapy with 65% of treated patients only prescribed one antihypertensive agent.93
- Disparities in BP control in the Americas also pose a challenge and arise from multiple sources. These include differences in healthcare systems, SES inequalities within countries, limited healthcare access in rural areas, and disparities in immigrant and visible minority populations compared with White populations. Countries within the Americas have differing models of healthcare with Canada having universal healthcare, and the highest hypertension control rates. The US healthcare system is largely privatized whereas Latin American countries provide both systems with ~80% receiving publicly funded care.102 In a meta-analysis of differing payer systems, reduced co-payments for healthcare, including medications, were associated with improved outcomes of hypertension.103 However, similar control can be achieved in HICs or middle-income countries, from the private sector or fully public initiatives, indicating that BP inequalities can be overcome with specific strategies.104,105 SES inequalities within countries are also associated with differences in hypertension control. Within the USA, hypertension prevalence was lowest among college graduates (39%) vs. those having a high school education or less (47%) and those with more than high school or some college (51%).24 Notably ~30% of adults with hypertension without health insurance were unaware of their hypertension compared with 14% of those insured. As healthcare visits increased, the percentage of adults with hypertension who were unaware of their status decreased.100
- Within countries, there is considerable variation in hypertension incidence, control and outcomes between rural and urban dwellers, immigrant vs. non-immigrant groups, and ethnic groups. The incidence of hypertension increased in rural populations, especially the rural...
southern USA, with 40% of adults in rural areas reported to have hypertension, compared with 29% in urban areas. This disparity is thought to be due to less access to healthcare and a lack of transportation in rural areas. In Canada, non-Hispanic black, and South Asians have a higher prevalence of hypertension and a younger age of onset compared with other groups. In the USA, hypertension prevalence remains higher among non-Hispanic Black (57%) than non-Hispanic White (44%) adults (applying the threshold of 130/80 mmHg). Non-Hispanic Black and Hispanic patients also had worse hypertension control than non-Hispanic White patients. Hypertension accounts for 50% of the racial differences in mortality between non-Hispanic Black and White populations in the USA. However, some ethnic groups possess a low risk of hypertension. The Kuna Indians of Panama exhibit an exceedingly low prevalence of hypertension (2%) thought to be secondary to a diet high in fruit, fish, low salt, and cocoa beverages compared with other Panamanians and Kuna Indians who transitioned to urban areas. Disparities vary by the ethnic group but are likely related to social determinants of health, access to care, salt sensitivity, and increased adiposity.

3.2.3 Opportunities to improve BP control
Initatives are needed to improve hypertension control that address BP disparities in underserved and marginalized populations using culturally appropriate approaches and improving practice level quality. Here, we outline four initiatives that could be scaled to a population level to achieve large impacts on BP control.

• Culturally tailored health promotion in non-traditional settings: Barbershops were used for health promotion to encourage African-American men to visit prescribing community pharmacists working in collaboration with physicians compared with encouraging patrons to visit their physician. Leveraging community pharmacists through trusted community lay people in a culturally specific environment was associated with superior BP control.

• Improving the quality of care in hypertension: The Kaiser Permanente model with simple algorithms, using SPCs, registries to monitor hypertension control rates at a practice level, feedback tools, and multi-disciplinary approach was associated with dramatic improvements in hypertension control compared with historical usual care. This informed the WHO HEARTS Technical package for wide-scale implementation.

• Optimizing virtual hypertension care: Given the widespread adoption of virtual care, optimization of virtual care delivery and adoption are urgently needed including improving digital literacy, especially in marginalized communities, increasing equitable access to broadband internet, home telemonitoring, and reimbursement models for care providers. Implementation of home telemonitoring with automatic teletransmission of BP measurements to their healthcare provider teams was associated with improved medication adherence and BP control.

• Development of national, low-cost antihypertensive medication programmes, which is feasible, given the relatively low cost of currently recommended medications.

3.3 Europe
Countries: Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Republic of Moldova, Romania, Russian Federation, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, UK.

3.3.1 Epidemiology
The prevalence of hypertension in Europe is strongly influenced by its ageing population and increased survival following cardiovascular events. Despite the documented improving trends for better BP control over the last 30–40 years, hypertension prevalence, awareness, and control in ageing European populations remains a considerable public health problem as recently documented again by the MMM screening campaign (Figure 4). A former North–South gradient of cardiovascular risk has been replaced by a West–East gradient during more recent decades, as exemplified by stroke (Figure 5).

This is mirrored by increasing prevalence rates of hypertension, stroke morbidity, and mortality in Eastern Europe and Russia. In most Western countries, there is a trend towards better control of BP in pharmacologically treated patients. This could represent more effective treatment, improved adherence, and better-educated patients seen in over the last 30–40 years. Although a further improvement of control rates is needed, the age-adjusted mean SBP is declining in Western Europe since the 1980s. Moreover, the age-adjusted prevalence rate of hypertension has not increased over recent decades. However, in Europe’s ageing population, the absolute number of patients with known hypertension has substantially increased, thereby imposing a heavy burden on healthcare in most countries.

In addition to the high-risk ageing population, other emerging risk groups are survivors of extreme preterm birth and congenital heart defects. Thanks to improved medical care in HICs, these individuals are now reaching adult age and will represent a novel group with strongly increased cardiovascular risk in the future.

The West–East gradient in hypertension prevalence exists in both the high- and male populations. A recent WHO-funded pooled analysis of data on BP levels and treatment in individuals aged 30–79 years derived from 1200 population-representative studies and covering the period from 1990 to 2019 revealed that the prevalence of hypertension in Eastern and some central European countries was 20–30% higher than in high-income Western European countries. While hypertension prevalence hardly differed between West and Central/East Europe and were generally high compared to the rest of the world (around 75% in all areas of Europe compared to only 59% worldwide), control rates differed significantly in these populations and were only 25% in women / 17% for men in central and Eastern Europe versus 45% in women / 37% for men in high-income Western countries (world wide control rates: women 23%, men 18%). Over the past three decades, despite observing an increase in the absolute number of hypertensive Europeans due to ageing and population growth, control rates have continuously improved for both sexes.
The change of political regime in Eastern Europe has led to challenges in the health reform of these countries, which has greatly affected the control of BP.

Another socially patterned problem is high alcohol consumption in many parts of Central and Eastern Europe, well known to associate with raised BP.

Obesity, another determinant of hypertension, is also socially patterned and often combined with high alcohol intake (extra calories) in the same parts of Europe. Indeed, it appears that the burden of obesity increased in Central and Eastern Europe with the accession to the European Union. These social determinants of health contribute to the suboptimal BP control rates in most European populations despite health cost coverage and the wide availability of low-cost antihypertensive drugs.

Figure 5 The West–East divide in Europe for stroke risk. (Republished with permission from Oxford University Press on behalf of the European Society of Cardiology. Data source: Institute for Health Metric Evaluation. All rights reserved.)
Ongoing political tensions and war in the Ukraine are anticipated to substantially impact local health systems and BP control in the region. The impact of war on cardiovascular health and hypertension care is widespread, with a direct relationship between combat wounds, war-related posttraumatic stress disorder, and increased risk of hypertension. However, the immediate and long-term effects of war on hypertension are apparent not only in service men and women but also has a direct impact on all affected people’s lives, safety, and freedom. The recent Russian invasion into an independent European state, Ukraine, is likely to translate into profound consequences on education, research, free movement, access to resources, breaking chains of medical supplies, and diagnostics affecting millions of lives. Due to the impact of this crisis, the ISH has published a message of solidarity with the Ukrainian people.

Salt intake is high in many European countries due to culinary traditions and easy access to processed food. This has influenced both prevalence of hypertension and the risk of stroke and other CVDs. In 2013, the WHO reviewed salt reduction activities across the European region, which prompted several countries, such as Portugal, to initiate health campaigns to reduce salt consumption and adopt legislative measures to reduce salt content in processed food. One of special benefit to salt-sensitive people. While it is too early to assess the effectiveness of the measures in Portugal, the Finnish North Karelia Project, which started in the 1970s, was shown to be very effective. This programme, which combined community-based interventions, national-level policy changes, and legislation on lifestyle measures (e.g. salt and saturated fat intake reduction, smoking cessation), achieved marked reductions in population salt consumption, BP, and cardiovascular mortality in 35- to 64-year-old men and women by 82 and 84%, respectively.

### 3.3.3 Opportunities to improve BP control

In some European countries (e.g. in Poland), extensive nationwide screening involving BP is current practice. This has contributed to an improvement in BP control. Other initiatives aimed at establishing national registers for certain groups of patients, for example, with diabetes mellitus, while also following up on BP control and antihypertensive treatments. One such example is the National Diabetes Register from Sweden since 1996, including BP data, both from hospitals and from primary health care.

The most important action to control BP in Europe is to have a well-structured and financed healthcare network around the hypertension patient involving mainly the primary healthcare physician, but also the hypertension specialist and pharmacist, among other caregivers of the patient for raising awareness, screening, diagnosis, treatment, and follow-up. An increased use of ABPM and home BP recordings can also contribute to better results, especially when integrated into digital health.

Evidence-based recommendations for diagnosis and treatment of hypertension and risk stratification in women are lacking as a direct consequence of too few enrolled women. For Europe, this is exemplified by the HOPE study, which had 73% European participants, but only enrolled around 26% women. Prevention of hypertension and its complications in Europe should focus on improving social conditions and the working- and living environment (including programmes to prevent alcoholism) in underserved populations. It is also important to apply a life-course approach starting with preventive maternal and child healthcare. Adverse factors in the early life of premature and growth-retarded newborn babies may lead to increased risk of hypertension in adult life. Many health benefits will be obtained by reducing global cardiovascular risk throughout the entire lifespan, as also emphasized by the Lancet Commission on Hypertension.

The geographical divide in cardiovascular risk in Europe, with higher incidence rates in Eastern Europe and Russia, calls for effective programmes involving recommendations for screening and treatment of hypertension. Finally, in ageing populations of Europe, many patients survive cardiovascular events and need effective treatment of remaining risk, including appropriate risk factor control. This also applies to the many comorbidities of elderly patients with hypertension, such as diabetes mellitus, CKD, and cognitive decline. The recommendation here is to have a multifactorial approach to reduce the overall risk based on guidelines. A summary of opportunities to improve BP control include:

- Support screening, diagnosis, treatment, and follow-up of hypertension throughout the healthcare network (including primary care, pharmacists, nurses, and paramedics), especially in the ageing populations of Europe. In countries with high awareness, patients may be further empowered by mobile application supporting BP monitoring, adherence, and lifestyle advice.
- Tailor screening programmes for hypertension to overcome health disparities in age, gender, social background, ethnicity, and access to health care—also found in HICs of Europe.
- Provide simplified treatment strategies and effective risk factor control, where BP control is part of a general preventive strategy.
- Support hypertension programmes in Central and Eastern Europe to reduce the burden of hypertension complications and excess cardiovascular risk that contributes to the West–East divide in cardiovascular health of Europeans.
- Implement national and regional registers to follow trends in hypertension prevalence, awareness and control, both in the population and in specific groups of patients, i.e. established CVD, diabetes, or CKD.

### 3.4 Middle-East and North Africa

Countries: Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Syrian Arab Republic, Tunisia, United Arab Emirates, Yemen

#### 3.4.1 Epidemiology

Hypertension is currently affecting ∼30% of the adult population in the Middle-East and North Africa (MENA) with wide variation between countries. This prevalence rate was also broadly reflected by the population of ∼140,000 participating in opportunistic screening as part of MMM (Figure 4), where only 31.9% of people with hypertension were controlled.

Within MENA, raised BP is causing an overburden on the medical system at governmental and individual levels as reported by the WHO. The early identification of hypertension requiring medical screening is more challenging in the region, as is estimating the representative incidence and prevalence rates for hypertension.

#### 3.4.2 Challenges

- The majority of the countries in the MENA region are classified as LMICs according to the World Bank definitions. In stable HICs, the burden of diagnosis and benefit of treatment of raised BP to the target levels required was clearly shown in early studies. The situation is very
different in LMICs with limited health budgets and health manpower.\textsuperscript{6} Getting the population in such communities to accept preventive medicine and seeking health screening are challenging and need robust efforts to change beliefs and behaviours. At the same time, it remains challenging to provide accessible and affordable health services.\textsuperscript{137–141}

- Wars and political instability have added an extra burden and led to deviating the attention towards the basics of living. Safety, food, and shelter became the main goals for a significant percentage of the population. Addressing screening and disease prevention became a commodity that has no place in the day-to-day living with the struggle for survival.\textsuperscript{4,7,136,141} Over the past decades, most of the regional conflicts which in some cases were military confrontations. This generated a wave of immigration and refugees that impaired further the provision of proper health services in that population sector.\textsuperscript{142} This is true even when families had moved to HIC. These resettlements increased the health burden around the area of conflict, where the baseline health expenditure and budgets, in most cases, are already stretched.\textsuperscript{143}

- When focusing on current practices to treat hypertension, these are highly ineffective and in the long term, will only increase the costs required to manage related organ damage and morbidities. The current measures and strategies are largely ineffective in many HIC, which illustrates that large-scale change in the detection and management of hypertension in HIC and LMICs are required.\textsuperscript{8} For that reason, urgent action plans are needed to expand allocated health budgets to be able to meet the increasing demands of managing raised BP and its complications. This is true for all countries within all economic levels.\textsuperscript{136,139}

- Another critical aspect relevant to the MENA region is the limited amount of research being conducted in general. There are major barriers such as modest funds allocated to research, as well as having urgent priorities for both the government and individuals related to conflicts.\textsuperscript{136} When systematically reviewing the literature, there are only limited data generated usually from HICs in the region. Hence, a large percentage of these numbers are not representative of the entire region. This is also highly relevant for regional guidelines that are often derived from global recommendations designed for an entirely different population.\textsuperscript{4,7}

### 3.4.3 Opportunities to improve BP control

With all these challenges mentioned, how can the MENA region be assisted in the fight against hypertension and its consequences?

- Local adoption of guidelines to define and classify hypertension considering the regional socioeconomic status and accompanying challenges—as described in the 2020 ISH guidelines.\textsuperscript{25} It should be understood how challenging it is to manage hypertension in an LIC as opposed to a stable HIC, where healthcare staff have to deal with patients from varying populations, standards of living, and genetic variation, with minimal resources.

- Research data are limited from participants and countries in the MENA region. Greater efforts should be spent on creating and maintaining accurate and timely epidemiological data on prevalence, treatment, and control rates. This includes raising funds from regional as well as global resources to support such activities. These figures would facilitate the creation and adoption of locally relevant guidelines.

- The age group subclassification of the MENA reflects that the largest proportion of the population are children, teenagers, and young adults. This situation is very different from ageing populations in HICs, and provides an opportunity to prevent raised BP through population-based initiatives while considering a life-course strategy.\textsuperscript{13} This could include early education and awareness programmes, campaigns, and seminars to provide knowledge on hypertension, and educating healthcare staff on the importance of early identification and advocacy towards a healthier lifestyle to prevent hypertension. A strategy targeting children may be the most cost-effective approach, but the benefits may take decades to realize. In the short term, funding would be essential to support these interventions that are likely to have a much greater cost–benefit ratio when compared with dealing with the consequences of hypertension later in the life-course.

- With limited local funding to support the education of primary care clinicians, nurses, and other health workers, funding support from pharmaceutical and medical companies would be crucial to provide continuous medication education to ensure best practices are followed in hypertension care.

- Broadening population screening and awareness programmes (such as the MMM campaign) or assigning specific screening clinics in LMICs in the MENA region would be an important step to increase awareness and treatment. Ideally, healthcare providers should receive thorough training on hypertension management including refresher courses, with a focus on preventive cardiology.

- A call to action is urgently needed with specific steps to stop the early development of hypertension to curb the tsunami of poorly controlled BPs.

### 3.5 South and Central Asia

Countries: Afghanistan, Bangladesh, Bhutan, India, Kazakhstan, Kyrgyzstan, Maldives, Nepal, Pakistan, Sri Lanka, Tajikistan, Turkmenistan, Uzbekistan

#### 3.5.1 Epidemiology

With a population of almost two billion, the South and Central Asia Region (SACA) is the largest region under the ISH’s remit in terms of population size. The region consists of heterogeneous ethnicities and income groups, most of them falling under the upper-middle to low-middle-income groups.\textsuperscript{144} According to WHO, the estimated age-adjusted prevalence of hypertension is \( \sim 27\% \) (ranging from 25\% in Bangladesh to 30\% in Pakistan).\textsuperscript{145} This figure is also reflected in the 31.3\% with hypertension in those participating in opportunistic screening as part of MMM (Figure 4). According to WHO, the awareness, treatment, and control rates vary substantially from 33 to 83\%, 30 to 70\%, and 7 to 30\%, respectively. Kazakhstan has the highest awareness (male: 80\%, female: 86\%), treatment (men: 66\%, women: 74\%), and control rate (men: 25\%, women: 34\%), whereas Nepal has the lowest rates for awareness (men: 30\%, women: 35\%), treatment (men: 16\%, women: 21\%), and control (men: 5.9\%, women: 8.5\%). Overall women have a higher BP control rate compared with men in all countries in the region.\textsuperscript{4}

#### 3.5.2 Challenges

Over the past three decades, the mortality rate due to hypertension in the SACA region has doubled.\textsuperscript{146} This population is burdened in terms of comorbidities, which comprise 70\% of patients with two or more comorbidities.\textsuperscript{147}

- It is estimated that \( \sim 50\% \) of hypertensive patients in the region do not adhere to medication.\textsuperscript{148} This is likely due to the huge gap between physician capacity and patient need for hypertension care as only physicians are allowed to prescribe antihypertensive medicines.\textsuperscript{149} Also, most of the countries in the region practice 1-month refillings for medication which may contribute to non-adherence.\textsuperscript{150}
Salt intake in the region is approximately double the WHO recommenda-
tion (<5 g/day), with a significant proportion of salt intake derived
from salt added during cooking and discretionary use at the
table.151 Although salt reduction initiatives have been proposed in sev-
eral countries of the region, they are yet to be fully implemented and
evaluated.
• The prevention and control of hypertension in the SACA region are
complex and differ vastly among countries, with strong regional, eco-

demic, and cultural influences. It is essential to close the gap in differ-
ce in practice and delivery of healthcare.

3.5.3 Opportunities
The region has the following opportunities to improve BP control:

• Strong collaboration between stakeholders,6,13 such as governmental
and non-governmental organizations, are important to implement
best practice strategies in preventing and managing hypertension.
The Indian Hypertension Control Initiative (IMCI) supported by
Resolve to Save Lives and implemented by the Government of India
is an example of such a collaboration.152
• Improved detection and management of raised BP by using large
population-based awareness and screening campaigns such as
MMM. Many countries in SACA who participated showed positive re-
sults with over 850,000 people screened in 2018 and 2019
(Figure 4).153
• Task sharing with non-physician health workers. Several studies from the
region consistently show that the engagement of non-physician
workers such as nurses and community health workers was cost-
effective and effective in reducing BP.154–157 New guidelines from the
WHO and ISH highlight the importance of team-based care, but
also treatment without laboratory investigations and self-
measurement by patients in resource-poor settings.25,158 However,
these guidelines are yet to be implemented in practice. The results
of an ongoing study in Nepal [NCT04521582] where community
health workers are prescribing antihypertensive medication could
have an important policy implication for task-sharing in the region.
• Population-based salt reduction efforts, including potassium salt
substitutes.
• Scaling-up of SPC therapies and multi-month prescription refill.
Countries should develop country-specific strategies to include
SPCs on country Essential Medicine Lists, aligned with the WHO
that added fixed-dose combination antihypertensive medication to
their Essential Medicine List in 2019.157 As the South Asian population
is at particularly high risk for CVD and metabolic diseases, clinical trials
are needed to recommend relevant treatment approaches.25
• Implementing universal health coverage. To finance hypertension
care, other countries in the region may learn from Sri Lanka and
Bhutan, that provide free hypertension care as part of their universal
health coverage,160 or alternatively should develop an equity-based
health insurance model.
• Implementing the WHO HEARTS technical package.

3.6 Asia Pacific
Countries/regions: Australia, Brunei Darussalam, Cambodia, China,
Cook Islands, Democratic People’s Republic of Korea (North Korea),
East Timor, Fiji, Indonesia, Japan, Kiribati, Laos, Malaysia, Marshall
Islands, Micronesia, Mongolia, Myanmar, Nauru, Niue, New Zealand,
Palau, Papua New Guinea, Philippines, Republic of Korea (South
Korea), Samoa, Singapore, Taiwan, Thailand, Taiwan, Vietnam

3.6.1 Epidemiology
Asia is a diverse continent, and the prevalence of hypertension has in-
creased over the last 30 years.166 BP levels per se have also increased
in Asian countries, being among the highest in the world.25
Furthermore, BP control in Asia is relatively poor compared with
Europe, Canada, and the USA (Figure 1). Even within the Asian region,
there is large heterogeneity in the awareness, treatment, and control
status of BP.154,161 partly due to relevant ethnic aspects and differences
in diet, lifestyle, and sociodemographic factors.

The slope of the association between BP and cardiovascular events is
steeper in Asians compared with Westerners.162 Data from the recent
STEP (Strategy of Blood Pressure Intervention in the Elderly
Hypertensive Patients) trial, conducted in China, showed that strict
BP control (systolic BP 110–130 mmHg) was superior to standard sys-
tolic BP control (130–150 mmHg) for preventing cardiovascular
events.163 This suggests that elderly Asians would benefit from strict
BP control to reduce cardiovascular risk.

3.6.2 Challenges
Several factors contribute to the development of hypertension and
CVD in Asia (Figure 6).144

• Higher salt intake and salt sensitivity: Asians are genetically predis-
posed to salt sensitivity.162 Salt intake is high compared with other
populations,164 and exceeds the WHO recommendations (<5 g/day).
For example, average salt intake is >10 g/day in Vietnam, China,
Korea, Japan, and Thailand.163

Partial or complete substitution of salt with potassium chloride is an
effective and simple way to reduce salt intake, and thereby BP and car-
 dovascular event rates.91 A digital therapeutic strategy designed to facili-
tate lifestyle modifications, including salt restriction and body weight
reduction, successfully reduced home and ABPM in patients with
hypertension.162

• Obesity: The body mass index threshold associated with an increased
risk of prehypertension and hypertension is 25 kg/m2 in Asians com-
pared with 30 kg/m2 for Westerners.162 Thus, body weight control,
especially in younger and middle-aged adults, is important for Asians.
• Hypertension phenotype: Masked hypertension is more prevalent in
Asian than in Western countries due to higher rates of abnormal pat-
terns of BP variability, including an exaggerated early morning BP surge
and non-dipper/riser phenotypes of nocturnal BP.162 Thus, identifying
and treating masked hypertension phenotypes seem particularly im-
portant for cardiovascular risk reduction in Asian populations.
Three prospective observational studies conducted in Asia (Oahasama, J-HOP, and HONEST) showed that morning hypertension
detected by HBPM is associated with a higher risk of CVD, regardless
of office BP.162 Another important feature of hypertension in Asian
populations is high night-time BP, which is commonly associated
with high salt sensitivity and salt intake. The presence of isolated noc-
turnal hypertension is a risk factor for organ damage and CVD even
when office and/or morning BP are well controlled.166 Nocturnal
hypertension is often found in high-risk patients with comorbidities
such as diabetes, CKD, sleep apnoea, and risk of heart failure.167
Better awareness, screening, and monitoring: Screening for hypertension in public places and self-measurement of BP using HBPM at home and/or the work site may help increase awareness.\textsuperscript{162,168} Results from MMM in Asia for over 1 million individuals screened in 2018 and 2019 (Figure 4) showed collectively that 34% had BP in the hypertensive range, with an overall control rate of 32.7%. For 2019, MMM data indicate a prevalence of hypertension of 30.6% in East Asia and 47.8% in South-East Asia and Australasia; corresponding hypertension awareness rates were 59.0% and 66.5%.\textsuperscript{153} Of patients with hypertension in the Asia Pacific, only 16.8–28.6% were on antihypertensive medication. For treated patients, 33.4% of those in East Asia and 36.8% in South-East Asia and Australasia had uncontrolled BP.\textsuperscript{153} Telemedicine may represent a valuable approach to help deliver effective care to patients with hypertension.\textsuperscript{162,169}

Increased uptake of telemonitoring: in the COVID-19 era, telemedicine has become a popular option to ensure patient and physician safety, and to facilitate infection control. Telemonitoring can be implemented more widely to improve access to care and patient outcomes. Wearable BP monitoring devices have great potential and are increasingly developed (although there are challenges to validate these devices for accuracy\textsuperscript{170}),\textsuperscript{162} and an ABPM technology platform has great potential to facilitate diagnostic and treatment decisions without the need for an office visit.\textsuperscript{169}

Salt intake reduction programmes:\textsuperscript{168} Most successful programmes include multicomponent strategies and are aligned with the WHO recommendations. Asian countries have implemented many programmes to reduce population salt intake.\textsuperscript{171} A significant reduction in salt intake in both children and adults was achieved through the School-based Education Program to Reduce Salt Intake in Children and Their Families (School-EduSalt) in China.\textsuperscript{172} The ‘Tokyo Declaration in Promotion of Salt Reduction’ recommended six strategies to achieve a salt intake of <6 g/day.\textsuperscript{173} The Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and hypertension-related diseases was announced in 2021.\textsuperscript{174} The impact of such programmes is shown by the National Health and Nutrition Survey of Japan, which showed small but gradual reductions in salt intake between 2005 and 2018, with a
The HOPE Asia Network was set up to improve the management of hypertension in Asia with the goal to achieve ‘zero’ cardiovascular events in the region. This resulted in the publication of several consensus documents and recommendations covering almost all major topics relating to the management of hypertension. The HOPE Asia Network model provides a good example of the local interpretation, modification, and dissemination of international best practice to benefit specific populations in collaboration with local hypertension societies.

### 4. Actions to ensure evidence-based hypertension care for cardiovascular risk reduction

This section will discuss evidence-based strategies to improve hypertension care for reducing CVD and eliminate related disparities among and within countries. To recommend such actions, a thorough understanding of global disparities in care is required.

#### 4.1 Reasons for global disparities in hypertension care among and within countries

The reasons for the global disparities in hypertension care are multifactorial and affect the populations at a different level in both LMICs and HICs. Some reasons include:

- **Social determinants**
  - Poverty
  - Food insecurity
  - Maternal malnutrition
  - Poor nutrition during periconception
  - Low education, unemployment, and health illiteracy
  - Racism
  - Effects of wars and political conflicts

- **Environmental determinants and commercial determinants**
  - Poorly planned urbanization and unregulated trade policies promoting unhealthy behaviours in the vast majority of the population
  - Tobacco
  - Calorie-dense diets
  - High salt diets
  - Sugar-sweetened beverages
  - Low fruit and vegetable consumption, high trans-fats and saturated fat intake, high alcohol consumption
  - Physical inactivity
  - Loss of green space
  - Air pollution

- **Health systems**
  - Grossly under-funded/non-existent public health for hypertension care.
  - Lack of implementable standardized clinical care for management of hypertension
  - Lack of social insurance for hypertension care
  - Out-of-pocket expenditure for antihypertensive medications and poor adherence
  - Shortage of qualified physicians and nurses
  - Knowledge gaps in hypertension care
  - Poor access to quality hypertension care in most countries
  - Lack of social insurance coverage for treatments that have better adherence, e.g. single-pill combination antihypertensive medications

- **Factors associated with disparities in hypertension care globally**

| Low-middle-income countries | High-income countries |
|-----------------------------|------------------------|
| **Social determinants**     | **Health systems**      |
| Poverty                     | Grossly under-funded/non-existent public health for hypertension care. |
| Food insecurity             | Lack of implementable standardized clinical care for management of hypertension |
| Maternal malnutrition       | Lack of social insurance for hypertension care |
| Poor nutrition during periconception | Out-of-pocket expenditure for antihypertensive medications and poor adherence |
| Low education, unemployment, and health illiteracy | Shortage of qualified physicians and nurses |
| Racism                      | Knowledge gaps in hypertension care |
| Effects of wars and political conflicts | Poor access to quality hypertension care in most countries |
|                            | Lack of social insurance coverage for treatments that have better adherence, e.g. single-pill combination antihypertensive medications |

- **Environmental determinants and commercial determinants**
  - Unhealthy behaviours promoted by social deprivation (listed above) specific to disadvantaged groups (low-income families, ethnic/racial subgroups):
    - High salt diets, sugar-sweetened beverages
    - Low fruit and vegetable consumption, high trans-fats and saturated fat intake, high alcohol consumption
    - Sugar-sweetened beverages
    - Physical inactivity, prolonged sitting time, and screentime
    - Loss of green space
    - Air pollution

- **Health systems**
  - Under-funded public health for hypertension care in some settings (e.g. the USA)
  - Gaps in some practices especially physician inertia to intensity treatment in patients with comorbidities
  - Clinician-patient communication barriers with racial/ethnic sub-groups
  - Variable access to quality hypertension care for disadvantaged groups
  - Insufficient social insurance coverage for highly efficacious treatments in some settings, e.g. single-pill combination antihypertensive medications, and more intensive BP monitoring (e.g. 24 h ambulatory and home monitoring)
  - Non-adherence to antihypertensive treatment

- **Factors associated with disparities in hypertension care globally**

- **Social determinants**
  - Neighbourhood poverty, low education, poor social support, unemployment in racial/ethnic, low-income groups, and migrants
  - Institutional racism in policies and practices at multiple levels

- **Environmental determinants and commercial determinants**
  - Unhealthy behaviours promoted by social deprivation (listed above) specific to disadvantaged groups (low-income families, ethnic/racial subgroups):
    - High salt diets, sugar-sweetened beverages
    - Low fruit and vegetable consumption, high trans-fats and saturated fat intake, high alcohol consumption
    - Sugar-sweetened beverages
    - Physical inactivity, prolonged sitting time, and screentime
    - Loss of green space
    - Air pollution

- **Health systems**
  - Under-funded public health for hypertension care in some settings (e.g. the USA)
  - Gaps in some practices especially physician inertia to intensity treatment in patients with comorbidities
  - Clinician-patient communication barriers with racial/ethnic sub-groups
  - Variable access to quality hypertension care for disadvantaged groups
  - Insufficient social insurance coverage for highly efficacious treatments in some settings, e.g. single-pill combination antihypertensive medications, and more intensive BP monitoring (e.g. 24 h ambulatory and home monitoring)
  - Non-adherence to antihypertensive treatment
HICs. A major challenge has been the overall public health emphasis on managing infectious diseases with inadequate focus on the detection and management of hypertension. The key factors are listed below and summarized in Table 5.

4.1.1 Social and environmental determinants during the life-course

Populations exposed to poverty, food insecurity, low education and health illiteracy, high rates of maternal malnutrition, and poor nutrition in the periconception period with accelerated post-infancy weight gain are particularly susceptible to hypertension and related CVD later in life. In addition, unplanned urbanization and poor trade policies promote unhealthy behaviours such as poor diet (high salt and low fruit and vegetable intake, high saturated and trans-fats), physical inactivity, tobacco and alcohol use, and obesity fuel the rise in BP over the lifespan. Pollution (air, water, noise, and light), psychosocial stress, and a loss of green space are emerging risk factors of hypertension. The long-term implications of climate change for both HIC and LMIC should not be underestimated by clinicians and policymakers, where extreme temperatures, flooding, and drinking water salinity may all impact BP and its control. Furthermore, people living in conflict zones (e.g. Afghanistan, Iraq, Libya, Palestine, Syria) or exposed to stressful conditions may have a higher risk of hypertension and CVD.

4.1.2 Health systems

Despite the demonstrated benefits of effective drug treatment and the existence of several international clinical practice guidelines, hypertension care indicators (awareness, treatment, and control rates) remain poor in many LMICs. The health systems performance in achieving better hypertension care correlates positively with a country’s economic development. From that perspective, countries in Latin America and the Caribbean (Brazil, Costa Rica, Ecuador, and Peru) have performed better relative to their gross domestic product (GDP) per capita whereas countries in SSA performed worst. In many countries in South Asia and Africa, healthcare is often sought through the poorly regulated private or informal sector. The rural areas have a shortage of qualified physicians and nurses. Moreover, serious gaps exist in the knowledge and practices of providers regarding the management of hypertension. For example, sedatives are used to treat hypertension by up to one-third of providers in Pakistan, and antihypertensive medications are often stopped once BP is controlled.

Donor-assisted funding for NCDs has been poor, with a budget discrepancy of 10:1 in favour of infectious diseases. Thus, local governments have not prioritized NCD prevention and control. For example, in South Asia, Africa, Vietnam, and Malaysia non-physician health workers offer immunization, family planning, and maternal and preventive child-care services; they do not have the training or mandate to deliver hypertension care.

In some countries, drug procurement is a significant challenge, even for the essential class of first-line antihypertensive drugs, such as ACE-I, not available in at least 16 LMICs. The lack of standardized clinical care algorithms that are implementable in the local context with wide variations in drugs used, doses, and brand names complicates individual treatment and makes bulk purchasing and supply chain logistics extremely difficult. Antihypertensive medications remain an out-of-pocket expense for many low-income families without social insurance, especially in Africa and South Asia. Poor adherence due to the cost of drugs is a significant patient-related barrier to BP control. Non-adherence is also one of the leading drivers of suboptimal BP control in HIC, although the main causes for non-adherence (i.e. polypharmacy) are possibly different to those in LMIC. Moreover, patient-related barriers such as the cost of travel to the clinics and the opportunity time of daily wage workers could impede access, especially for men who are less likely to be treated for hypertension than women. There is little evidence on the cost-effectiveness of screening for hypertension in these LMICs settings unless accompanied with health systems strengthening for treating hypertension and ensuring access to medications. Thus, outreach efforts with non-traditional models of hypertension care delivery at home or worksite need to be considered.

Multiple studies have shown that most patients with hypertension, especially those with obesity or comorbidities, require more than one drug to control BP.

SPC drugs with flexible doses of two antihypertensive medications, many of which are off-patent and hence relatively low cost, improve adherence and possibly BP control. Major international hypertension management guidelines recommend SPCs. However, in most LMICs, different SPCs are not available and are not subsidized. Moreover, the widespread use of SPC drugs requires a robust health-care delivery infrastructure which does not exist in many LMICs.

4.1.3 Race/ethnic-based and social inequities in policies and practices related to hypertension and CVD

The racial/ethnic inequities in hypertension and CVD relate primarily to social and economic factors such as neighbourhood poverty, low education, poor social support, unemployment, being uninsured, lack of affordability, psychosocial stressors due to racism and with unhealthy behaviours and poor adherence to medications. Moreover, almost 30 million people from low-income families in the USA are still without any form of health insurance and Blacks and Hispanics are 1.5 and 2.5 times, respectively, more likely to be uninsured than Whites, and therefore with poor access to hypertension care.

These disparities were further unmasked during the COVID-19 pandemic, which affects people with hypertension-related CVD preferentially and led to disproportionately more deaths in Black, Latino, South Asian, and other populations in the USA, UK, Europe, and Canada, attributed in part to institutional or structural racism. The latter refers to practices and policies of institutions, workplaces, and health systems that chronically place certain racial/ethnic groups at a disadvantage. The adverse experiences, even if perceived, are associated with psychosocial stress, mistrust in healthcare, suboptimal adherence to antihypertensive medications, and poor outcomes.

4.2 Way forward and call to action

Immediate action is needed to address suboptimal hypertension care globally and related disparities. The WHO’s Global Action Plan for Prevention and Control of NCDs aims to reduce the prevalence of hypertension by 25% by 2025, relative to 2010. Subsequently, the United Nations’ Sustainable Development Goal (SGD) 3.4 aims to reduce premature CVD mortality by 30% by 2030; relative to 2010. Improving BP control by 50% is central to achieving this goal. However, many LMICs have not observed any improvement in hypertension burden or BP control (Figure 1). In HIC, gaps in hypertension control and inequities persist, which need to be bridged. It is possible to achieve prevention and control of hypertension through multifaceted, cost-effective efforts, including population-level policy initiatives and health systems strategies targeting high-risk individuals. For example, a
recent modelling study showed that three essential public health interventions, including reducing sodium intake by 30%, eliminating the intake of artificial trans-fatty acid, and improving coverage of antihypertensive drugs to 70% could save millions of lives by preventing NCDs.195

We recommend the following actions for improving BP awareness, treatment, and control rates by at least 30% by 2030, relative to 2015, for CVD risk reduction, and a particular focus on eliminating related disparities (Figure 7).

1. Make reduction in inequities in hypertension care a global, regional, national priority.

We propose a Global Hypertension Care Task Force jointly led by WHO, ISH, and other professional societies. The Task Force would facilitate policy dialogues and measures, including technical assistance to catalyse improvement in BP control rates. In addition, every country should establish a dedicated national coordinating centre for stewardship and implementation of the hypertension prevention, detection, and control agenda with effective outreach to the disadvantaged populations at high risk of hypertension and national surveillance and reporting of standardized hypertension care indicators. The centre would also facilitate policy dialogues with the governments, set targets for priority programmes and policies according to the local context, and advocate for large-scale implementation of well-funded programmes to eliminate inequities in hypertension care.

2. Implement national policies and interventions to reduce dietary salt, sugar-sweetened beverages (SSB), obesity, tobacco, alcohol, saturated and trans-fats, and increase consumption of fruit and vegetables intake and physical activity. Support the eradication of social and institutional racism.

Lifestyle modification is essential and less costly for the prevention and non-pharmacological treatment of hypertension. Policy strategies for hypertension prevention require multi-sectoral processes, including taxation and subsidies, marketing healthy foods, and improving the built environment to promote physical activity.

(a) Dietary salt: In patients with hypertension, a high salt intake is associated with a higher risk of CVD and death.91,196,197 The WHO has designated a reduction in salt intake to <5 g/day as a ‘best buy’, i.e., one of the most cost-effective and affordable interventions to avoid premature deaths and reduce the economic impact of NCDs. In HICs, the primary source of dietary salt is via packaged foods and food and sauces prepared outside the home. Policy-level interventions, especially food product re-formulation, have been successful in HICs, for example, in Finland.198 About 75 countries have a national policy to reformulate food to lower dietary salt, albeit implementation is at different stages. However, in LMICs, more than half of dietary salt is from discretionary sources added while cooking or at the table.199 Of note, African and Asian populations may have more salt-sensitive hypertension, and average salt intake is higher in Asian countries (e.g. >12 g/day in China).200 As of 2015, almost half of the 1.13 billion people with hypertension lived in South Asia or East Asia.2 The Salt Substitute and Stroke Study (SSaSS) study conducted in rural China demonstrated the benefit of substituting traditional salt with potassium salt on BP and CVD event rates.91 Not only did this intervention reduce sodium intake, but it addressed suboptimal potassium intake as experienced in high-200 and low-201-resource settings, with higher potassium contributing to BP lowering.

(b) Tobacco control: Although not causally related to high BP, tobacco control is one of the most cost-effective legislative strategies for CVD risk reduction in the general population and for those with and at risk of hypertension.202 Although 168 countries have ratified the WHO’s Framework Convention Tobacco Control (FCTC), more than 40% of LMICs do not ban advertising cigarette advertising.203

(c) Trans-fats, alcohol, sugar, and SSB consumption: Reducing trans-fat consumption is expected to lower CVD mortality in patients with hypertension.204 The primary source of trans-fat is partially hydrogenated vegetable oils which are cheap to produce and have a long shelf life, and therefore more profitable for the food industry.205 WHO recommends a complete ban on trans-fats, or a maximum limit of 2% trans-fat in all foods. Likewise, avoiding binge drinking and reducing alcohol to less than two daily drinks lower BP and reduces deaths. Increasing taxes and prices reduces alcohol consumption.206 Sugar and SSB taxes are projected to have substantial health gains.207 Over 40 countries, including Mexico, South Africa, the Philippines, and India, have implemented taxation on SSB, projected to reduce obesity and associated elevated BP.208

(d) Fruit and vegetable intake: Based on the results of the Dietary Approaches to Stop Hypertension (DASH) trial, a diet rich in fruit and vegetable is recommended for lowering BP.197 However, the cost of one serving of vegetables and fruits relative to income per household member is several-fold higher in LMICs than in HICs, respectively.17,209,210 Trade policies and subsidies must protect the affordability of the seasonal produce for the local populations, with government subsidies for the marginalized high-risk racial and low-income groups.

(e) Physical activity and school-based nutritional programmes: Systematic reviews of RCTs on school-based lifestyle interventions, including increasing physical activity, show a beneficial impact on BMI and BP.211 Parental involvement augmented the beneficial effects of interventions.212 Policies to ensure safe urban built environments will not only promote easier physical activity in the youth, but across the whole population.13

(f) Eliminate racial and social injustice in hypertension care: Finally, racism needs to be viewed as a social problem, not a biological construct.10 Proactive anti-racism measures are required to ensure health equity in hypertension care through advocacy, policies, and practices that proactively engage ethnic/racial groups and low-income families. Such measures include contextually tailoring interventions to ensure effective hypertension care delivery to disadvantaged populations.10

3. Strengthen health systems and implement a well-designed quality-of-care improvement framework and ensure outreach to specific racial/ethnic groups and low-income populations that is sustainable and cost-effective.

Strengthening health systems using a well-designed quality-of-care improvement framework that addresses multiple barriers to hypertension care is essential. In addition, such efforts must ensure outreach to the disadvantaged populations, including low-income and racial/ethnic groups, and be cost-effective, acceptable, affordable, and sustainable.
The following evidence-based health systems interventions are likely to be most impactful in reducing the burden of uncontrolled hypertension and CVD, and related disparities:

(a) Scaling-up evidence-based, non-traditional models of hypertension care with task-sharing tailored to the local setting.

Several studies and systematic reviews of randomized trials evaluating health systems strategies have shown that single interventions such as training physicians alone, or patient education alone, have modest to no benefit on BP control.212 However, combined interventions including team-based approaches addressing multiple barriers to BP control are likely to yield clinically meaningful BP lowering and CVD risk reduction.212–214

The Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka (COBRA-BPS) trial evaluated a multicomponent intervention including the non-traditional model of trained community health worker-led HBPM, home health education underscoring lifestyle modifications and adherence to antihypertensive medications, and trained physicians tailored to the local public health care infrastructure. The intervention improved BP control by 22% over 2 years and was cost-effective and affordable (less than US$2 per capita annually).154,156

The intervention also improved antihypertensive medication intensification, and some aspects of quality of life. Likewise, several studies have shown benefit of task-sharing approaches with community health workers delivering hypertension care via BP monitoring, lifestyle counselling, and linkage to clinics in urban communities in Argentina, India, Nepal, Pakistan, and Kenya.104,155,215,216 More recently, the benefit of a community health worker-led multifaceted intervention on BP control has also been demonstrated in rural villages in China.217

Non-traditional models of care are effective in racial minorities in HICs as well. In the USA, pharmacist-led, barbershop-based hypertension care has been shown to successfully lower BP in high-risk Blacks with hypertension relative to usual care,112 albeit sustainability and cost-effectiveness of the approach remain to be established.112

Thus, scaling-up non-traditional models of care tailored for disadvantaged populations will likely reduce disparities in BP control and CVD substantially.

(b) Ensure universal access to antihypertensive medications including initial SPC therapy:

Antihypertensive medications must be available at no or subsidized cost to patients in primary healthcare centres. Universal health coverage, including access to quality and affordable essential medicines for all, is advocated by United Nations’ Sustainable Development Goals.194 Adherence to antihypertensive treatment must be promoted through both scheduled and opportunistic interactions between patients and healthcare professionals given the potential positive impact of better adherence on BP control in individual patients218 and healthcare systems.219 There are new direct objective diagnostic approaches to detecting, monitoring and management of non-adherence to antihypertensive treatment including self-HBPM but they are currently only routinely available in some HICs. More research is required to develop affordable and scalable diagnostic methods and therapeutic interventions for non-adherence to antihypertensive treatment in LMICs.

Health insurance reforms must include universal coverage for hypertension care, including non-traditional models integrated into primary care, and reduce out-of-pocket expenditure for antihypertensive drugs. Some examples of quality access for hypertension care include health systems in Canada, and Scandinavian countries, albeit racial/ethnic disparities need improvement. In addition, the hypertension quality improvement programme with SPC antihypertensive medications in the Kaiser Permanente network in California showed marked improvement.
in BP control.\textsuperscript{113} Such models could be adapted in Central and Eastern Europe, North Africa, and the Middle East to bridge the gap between high BP awareness and control rates.

(c) Leverage existing infrastructure and opportunistic approaches to deliver hypertension care.

Leveraging the existing platform offers an opportunity to achieve population-level prevention of hypertension at marginal costs.\textsuperscript{220} The partnership between WHO’s Global Hearts Initiative with Resolve to Save Lives to produce the HEARTS Technical Package provides essential modules for training health providers.\textsuperscript{221} The partnership between WHO and Resolve to Save Lives has shown promising results with an additional 3 million people on hypertension treatment. The impact of this programme on improving BP control needs evaluation.

Opportunistic screening, awareness, and treatment of hypertension should also be encouraged by leveraging existing infrastructure for maternal and child health services, and infectious diseases (e.g. COVID-19, HIV, tuberculosis), public–private partnerships should be encouraged (e.g. worksite) to provide for unmet needs in special populations.\textsuperscript{220} For example, delivery of hypertension care could leverage the HIV care infrastructure funded by the US President Emergency Preparedness Funds for Aids Relief (PEPFAR) in SSA, where hypertension awareness is poor, while the burden is rising steeply.

(d) Improve digital health literacy for future innovations in digital health, HBPM.

Evidence is accumulating on the potential benefit of digital health interventions for hypertension care. For example, smartphone use by the health workers and patients for virtual follow-ups improves adherence to antihypertensive medications and linkage to clinics.\textsuperscript{222} More than 80\% of the population of LMICs have mobile phones, and a large majority of villages are connected with mobile technology.\textsuperscript{215} Telemonitoring is especially valuable during the social distancing requirements imposed by the COVID-19 pandemic with dropping clinic attendance. However, there are concerns regarding the potential widening of disparities racial and ethnic populations may not be tech-savvy.\textsuperscript{36} Therefore, measures to enhance digital literacy and additional solutions are needed for regions and people where information technology is still under-deployed or underserved.

The use of home BP monitors improves treatment adherence and BP control when coupled with other interventions and need to be used more widely.\textsuperscript{223} ABPM (24 h, daytime, or night-time) is a better predictor of long-term CV outcomes than clinic BP\textsuperscript{224} and is recommended by the Canadian Hypertension Education Program in 2005 and NICE guidelines in 2011 for diagnosis of hypertension. However, the feasibility and cost-effectiveness of scaling-up ABPM relative to office BP or HBPM, particularly for repeated use in the long-term management of hypertension, remain to be studied in most settings including in HICs.\textsuperscript{10}

5. Conclusion

Based on robust empirical data and modelling studies, progressive implementation of affordable, and equitable hypertension care between 2020 and 2030 could save the lives of more than 100 million people aged 30–70 years, who would otherwise die prematurely, and help achieve the Sustainable Development Goal 3.4.\textsuperscript{195} Such efforts would also reduce the hypertension-related disability burden on all health systems. Therefore, WHO and country leadership should prioritize improving the implementation of national programmes for hypertension care with outreach to the marginalized communities. They must also facilitate robust accountability and monitoring to achieve the targets and institutionalize establishing a national registry and surveillance on hypertension.

Additional research should be encouraged on novel therapies and rapidly scalable, low-cost interventions for eliminating inequities in hypertension care. These studies must also record patient-reported outcomes. Major donors, including the World Bank and Gates Foundation, need to invest in large programmatic initiatives to fight hypertension—the world’s biggest silent killer.

Supplementary material

Supplementary material is available at Cardiovascular Research online.

Authors’ contributions

A.E.S., B.W., and M.T. conceptualized the design and paper outline; N.R.P., A.D., N.A.K., P.M.N., J.A., D.N., K.K., and T.H.J. led the different sections. The following authors contributed to drafting the different sections: Lessons learnt (G.S., R.M.T., T.J.G., H.I., N.R.P.); SSA (A.D., E.S.W.J., A.O.); Americas (N.A.K., C.S.M., B.M.W., D.B., R.D.W.); Europe (P.M.N., S.B., U.M.S., T.I.U.); MENA (J.A., G.H., A.S.); SACA (D.N., M.P., U.R., M.I.); Asia Pacific (K.K., J.-G.W., M.P.S., C.S.M., P.K.); Action for cardiovascular risk reduction (T.H.J., H.B., F.J.C., E.M., T.K.). All authors drafted and reviewed the manuscript critically and gave final approval of the paper to be published.

Collaborators (internal document reviewers): George Bakris (USA); Norm Campbell (Canada); Thomas Beaney (UK); Claudio Borghi (Italy); Lizzy Brewster (Netherlands); Lebo Gafane-Matemane (South Africa); Krasimira Hristova (Bulgaria); Alexandra Konradi (Russia); Reinhold Kreutz (Germany); Michael Hecht Olsen (Denmark); Raj Padwal (Canada); Priscilla Prestes (Australia); Nicolás Renna (Argentina).

Conflict of interest: A.E.S. received speaker honoraria from different pharmaceutical companies and device manufacturers for work unrelated to this paper; P.M.N. has received speaker honoraria from different pharmaceutical companies. K.K. reports research grants from A&D, Omron Healthcare, Fukuda Densi, Otsuka Pharmaceutical, Otsuka Holdings, CureApp, Sanwa Kagaku Kenkyusho, Daichi Sanky, Taisho Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Boehringer-Ingelheim Japan, Pfizer Japan, Fukuda Lifetec, Bristol-Myers Squibb, Mochida Pharmaceutical, Roche Diagnostics; and Consulting fees from A&D, JJMRO, Omron Healthcare, CureApp, Kyowa Kirin, Sanwa Kagaku Kenkyusho, Terumo, Fukuda Densi, Mochida Pharmaceutical; and Honoraria from Idorsia, Omron Healthcare, Daichi Sanky, Novartis Pharma, Mylan EPD; and Participation in Advisory Board of Daichi Sanky, Novartis Pharma, Fukuda Densi outside the submitted work. J.-G.W. reports having received lecture and consulting fees from Novartis, Omron, Servier, and Vitatr. M.P.S. has received consulting fees, and/or travel and research support from Medtronic, Abbott, Metavention, ReCor, Novartis, Servier, Pfizer, and Boehringer-Ingelheim. E.S.W.J. has received honoraria from pharmaceutical companies for work unrelated to this publication. N.R.P. has received financial support from several pharmaceutical companies which

Downloaded from https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvac130/6758338 by University of Cape Town Libraries user on 18 October 2022
manufacture BP-lowering agents, for consultancy fees (Servier), research projects, and staff (Servier, Pfizer) and for arranging and speaking at educational meetings (AstraZeneca, Lti Therapharma, Napi, Servier, Sanofi, Eva Pharma, Pfizer, Glenmark Pharma, Alkem Lab, and Emcure India). He holds no stocks and shares in any such companies. This manuscript was handled by Guest Editor Thomas F. Lüscher.

Acknowledgements

The authors would like to thank Dr James Eales for creating Figure 1.

Funding

M.T. receives grant support from the British Heart Foundation (CS/17/3/32799). T.H.J. receives grant support from the Singapore National Medical Research Council (NHMRC). R.D.W. receives grant support from the National Institutes of Health (NIH). M.P.S. was supported by a Research Fellowship of the National Health and Medical Research Council (NHMRC) of Australia.

Data availability

Since this paper is a preprint paper there is no data to be made available.

References

1. Global Burden of Disease Risk Factor Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1223–1249.
2. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 191 million participants. Lancet 2017;389:37–55.
3. Moran AE, Forouzanfar MH, Roth GS, Mensah GA, Ezzati M, Murray CJL, Lozano R. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
4. Schipperus MR, Thomas S, Kromhout D. Evidence for a graded association between systolic blood pressure and all-cause mortality in middle-aged and older adults: a meta-analysis of 41 prospective studies. J Hypertens 2018;36:1089–1093. doi:10.1093/jhy/hnx111.
5. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
6. Schipperus MR, Thomas S, Kromhout D. Evidence for a graded association between systolic blood pressure and all-cause mortality in middle-aged and older adults: a meta-analysis of 41 prospective studies. J Hypertens 2018;36:1089–1093. doi:10.1093/jhy/hnx111.
7. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
8. Schipperus MR, Thomas S, Kromhout D. Evidence for a graded association between systolic blood pressure and all-cause mortality in middle-aged and older adults: a meta-analysis of 41 prospective studies. J Hypertens 2018;36:1089–1093. doi:10.1093/jhy/hnx111.
9. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
10. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
11. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
12. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
13. World Health Organization. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018): e361–e745. doi:10.1016/S0140-6736(18)32037-6.
Jafar TH, Gandhi I, Jehan I, Naheed A, de Silva HA, Shahab H, Alam D, Luke N, Wei L. Children in South Asia have higher body mass-adjusted blood pressure levels than white children in Western Europe, in: proceedings of the 9th World Hypertension Conference, 2020; 66:126-1279.

McLaren L, Barberio A, Webster J. Salt reduction initiatives around the world - a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 2013;3:e003733.

Trieu K, Neal B, Hawkes C, Dunford E, Campbell N, Rodriguez-Fernandez R, Legetic B, McLaren L, Barberio A, Webster J. Salt reduction initiatives around the world - a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 2013;3:e003733.

Zhang W, Li Y, Li C, Wu J, Ma J, Zhang B, Wang H, Li Y, Han J, Luo R, He J, Li X, Liu D. The in... of the Asian Hypertension Society Network: the Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and the prevention and control of hypertension: evolving technological platforms for blood pressure telemonitoring. Hypertension 2011;58:54-57.

Jeemn T, Sivam K, Amodeo C, Balabanova D, Campbell NRC, Gaita D, Kario K, Khan T, Mellemlien R, Moran A, Papanicolaou P, Perez P, Perile P, Dintio JF, Schutte AE, Wyss FF, Yuen YL, Poulter NR, Prabhakaran D. Statement of the Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and the prevention and control of hypertension: evolving technological platforms for blood pressure telemonitoring. Hypertension 2011;58:54-57.

Breeze E. Inequalities persist in Europe-and COVID-19 does not help. BMJ 2021;373:n936.

Bakris G, AI, Wari G, Accu/HEA versus ESC/ESH on hypertension guidelines: ACC guideline comparison. J Am Coll Cardiol 2019;73:3018-3026.

Warren RC, Forlow L, Hodge DA Sr., Truog RD. Trustworthiness before trust - COVID-19 vaccine trials and the black community. N Engl J Med 2020;382:e121.

Lung T, Jan S, de Silva HA, Guggal R, Mailik PK, Naik N, Patel A, da Silva AP, Rajapakse S, Ransinghe G, Prabhakaran D, Rodgers A, Salam A, Selak V, Steens T, Thoms A. The systematic evaluation of temporary migrant agricultural workers in Canada: exacerbation of health vulnerabilities during the COVID-19 pandemic and recommendations for the future. J Med Health Care 2021;2:100035.

Frieden TR, Cobb KL, Leidig RC, Mehta S, Krick D. Reducing premature mortality from cardiovascular and other non-communicable diseases by one third: achieving sustainable development goal indicator 3.4.1. Global Health 2020;15:50.

Kontis V, Cobb KL, Mathers CD, Frieden TR, Ezzati M, Danaei G. Mitigating ethnic disparities in blood pressure: a systematic review of data from four studies. Lancet 2005;366:1278-1282.

Frezee E. Inequalities persist in Europe-and COVID-19 does not help. BMJ 2021;373:n936.

Bakris G, AI, Wari G, ACCu/HEA versus ESC/ESH on hypertension guidelines: ACC guideline comparison. J Am Coll Cardiol 2019;73:3018-3026.

Warren RC, Forlow L, Hodge DA Sr., Truog RD. Trustworthiness before trust - COVID-19 vaccine trials and the black community. N Engl J Med 2020;382:e121.
